SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced five upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2018 Annual Meeting being held in Atlanta, Georgia from June 7 to 11, 2018.
| Poster Talk | ||
| Title: | Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2 and 3 Studies, Trang et al | |
| Session: | Session 379-Clinical PK/PD Studies, June 10, 2018, 1:05 pm - 1:15 pm ET | |
| Poster Presentations | ||
| Title: | Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Plazomicin Dose Selection and Recommendations for Interpretive Criteria for In Vitro Susceptibility Testing for Enterobacteriaceae (ENT), Bhavnani et al | |
| Session: | Session 409-AAR04-Antimicrobial PK/PD & General Pharmacology: Clinical Studies, June 10, 2018, 12:45 - 2:45 pm ET | |
| Title: | Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide, Castanheira et al | |
| Session: | Session 236-AAR09-Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents between Phase 2 and FDA Approval, June 9, 2018, 11:00 am ET - 1:00 pm ET | |
| Title: | Evaluation of Plazomicin (PLZ), Tigecycline (TGC), and Meropenem (MEM) Pharmacodynamic (PD) Exposure against Carbapenem-Resistant Enterobacteriaceae (CRE) in Evaluable Patients from the CARE Study (ACHN-490-007), Kuti et al | |
| Session: | Session 236-AAR09-Pharmacological Studies of Antimicrobial Agents Pre-NDA (Phase 2/3): New Agents between Phase 2 and FDA Approval, June 9, 2018, 11:00 am ET - 1:00 pm ET | |
| Title: | A Multi-Site Study Comparing a Commercially Prepared Dried MIC Susceptibility System to the CLSI/ISO Broth Microdilution Method for Plazomicin Using Non-Fastidious Gram-Negative Organisms, Andrus et al | |
| Session: | Session 042-CPHM02-Antimicrobial Susceptibility Testing: Gram-Negative Bacteria, June 8, 2018, 11:00 am - 1:00 pm ET | |
The abstracts can be accessed through the ASM Microbe website. Following the meeting, the posters will be available on the Achaogen website.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen's plazomicin program has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201000046C. The Company's second product candidate C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination, is funded in part with federal funds from BARDA. Achaogen has other programs in early and late preclinical stages of development focused on MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen's expectations regarding potential regulatory approval of its product candidates and Achaogen's commercial objectives. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any future results. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process and the risks and uncertainties of the regulatory approval process. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 27, 2018 and its Quarterly Report on Form 10-Q filed on May 7, 2018. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Achaogen, Inc.
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
arr@lifesciadvisors.com
Media Contact:
Denise T. Powell
Red House Consulting, LLC
dpowell@achaogen.com